Chinese Omicron-specific mRNA COVID vaccine candidate to be trialed in UAE

Published by

BEIJING (Reuters) – China’s Suzhou Abogen Biosciences Co said its COVID-19 vaccine candidate using the messenger RNA (mRNA) technology and targeting the Omicron variant has obtained clinical trial approval in the United Arab Emirates. With Friday’s announcement, Abogen joins Pfizer/BioNTech and Moderna in trialing candidates modified specifically against Omicron, a highly transmissible variant with increased resistance to antibodies elicited by existing shots. Mainland China has vaccinated over 88% of its 1.4 billion people against COVID with non-mRNA shots. It has not approved any foreign vac…

Read More

Leave a Reply